What Aardvark Therapeutics does

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2017 by Dr. Tien Lee, MD, headquartered in San Diego, California, and listed on NASDAQ under ticker AARD following its 2025 IPO. The company develops oral small-molecule therapies that activate bitter taste receptors (TAS2Rs) expressed on enteroendocrine cells in the gut lumen, triggering local release of satiety hormones (CCK and GLP-1) that engage gut-brain vagal signaling to suppress hunger. Its lead compound ARD-101 is restricted primarily to the digestive tract with approximately 1% systemic exposure, a design intended to minimize off-target toxicities relative to systemic CCK analogues.

The pipeline is built around ARD-101, which has received FDA Orphan Drug Designation and is being evaluated in the Phase 3 HERO trial for hyperphagia in Prader-Willi Syndrome (with development also directed at Hypothalamic Obesity). ARD-201 extends the platform into general obesity as an oral once-daily fixed-dose combination of ARD-101 with a DPP-4 inhibitor (POWER trial for weight maintenance, STRENGTH trial for weight loss). Earlier-stage assets include WE-868 (metabolic/obesity) and DIA-615, a topical candidate for inflammatory skin diseases such as psoriasis that was placed in the newly formed wholly-owned US subsidiary Ardia Therapeutics in February 2026. Phase 3 HERO enrollment was expanded in late 2025 to sites in the US, Australia, Canada, and the UK.

Aardvark has no approved products and no commercial revenue, making it pre-revenue with a business model contingent on future commercialization through specialty drug sales and/or licensing royalties once regulatory approval is secured. The company has raised approximately $129 million in venture funding across its Series B (Sorrento-led, $29M in 2021) and Series C (Decheng Capital-led, $85M in 2024) prior to listing. Its clinical programs have been materially disrupted in 2026 by a voluntary pause of the Phase 3 HERO trial in February 2026 and a subsequent FDA full clinical hold on the ARD-101 IND in May 2026, both tied to reversible cardiac safety signals, with related securities-fraud investigations now underway.

Name

Aardvark Therapeutics

Legal name

Aardvark Therapeutics, Inc.

Website

https://aardvarktherapeutics.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecules that activate gut bitter taste receptors (TAS2Rs) to suppress hunger, targeting rare metabolic disorders and obesity. Its lead candidate ARD-101 is under an FDA clinical hold following cardiac safety signals.

Ownership category

akta.pro rank

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. None — Pre-Revenue Clinical Stage: Aardvark Therapeutics is a clinical-stage biopharmaceutical company with no approved products and no current revenue. The company reported a net loss of $57.6 million for full-year 2025 and $21.6 million for Q1 2026, with R&D expenses of $48.9 million in 2025. Future revenue is expected to come from commercialization of ARD-101, ARD-201, and other pipeline assets (likely a mix of specialty drug sales and potential partnership/licensing income) once regulatory approval is obtained.

Go-to-market motion1 record

Core offering

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies that activate bitter taste receptors (TAS2Rs) on enteroendocrine cells in the gut to trigger local release of satiety hormones (CCK and GLP-1), activating gut-brain signaling that suppresses hunger. Its lead candidate ARD-101 is gut-restricted (~1% systemic exposure) and is in development for hyperphagia in Prader-Willi Syndrome (HERO Phase 3) and Hypothalamic Obesity, while ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, targets obesity and weight maintenance. Additional pipeline assets include WE-868 in metabolic disease and DIA-615 in dermatology (inflammatory skin diseases).

Product overview

Aardvark Therapeutics operates a clinical-stage biopharmaceutical pipeline rather than a unified commercial software platform. Its portfolio centers on proprietary, orally delivered small molecules that activate bitter taste receptors (TAS2Rs) in the gut to trigger satiety hormone release and suppress hunger. The lead asset ARD-101 anchors the pipeline and is being studied in the HERO Phase 3 trial for hyperphagia in Prader-Willi Syndrome, with additional development in Hypothalamic Obesity. ARD-201 extends this approach into obesity as an oral once-daily fixed-dose combination of ARD-101 with a DPP-4 inhibitor (POWER trial for weight maintenance; STRENGTH trial for weight loss). Earlier-stage pipeline assets WE-868 (metabolic/obesity) and DIA-615 (a topical dermatology candidate for inflammatory skin diseases such as psoriasis, housed in the newly formed subsidiary Ardia Therapeutics) round out the company's portfolio of hunger- and inflammation-associated programs.

Differentiator

Problem solved

Functional benefit

Brands

• Ardia Therapeutics: Wholly-owned U.S. subsidiary developing the dermatology pipeline led by DIA-615, a topical treatment for inflammatory skin diseases including psoriasis.

Products and services

• ARD-101 Oral, gut-restricted investigational small-molecule TAS2R agonist that activates bitter taste receptors on enteroendocrine cells in the gut, triggering local release of satiety hormones (CCK and GLP-1) and gut-brain signaling to suppress hunger. Lead indication is hyperphagia in Prader-Willi Syndrome (Phase 3 HERO trial); also in development for Hypothalamic Obesity. Approximately 1% systemic exposure, designed to minimize off-target toxicity. FDA Orphan Drug Designation granted.
• ARD-201 Investigational, fixed-dose once-daily oral combination of ARD-101 with a DPP-4 inhibitor, being developed for obesity and obesity-related conditions. POWER trial evaluates weight maintenance after GLP-1 discontinuation; STRENGTH trial combines sitagliptin with TAS2R agonism for weight loss.
• WE-868 Pipeline compound within Aardvark's metabolic/obesity portfolio, advancing in clinical development for obesity and metabolic diseases and referenced alongside ARD-101 and ARD-201 in ObesityWeek 2025 presentations.
• DIA-615 Lead asset of Ardia Therapeutics, Aardvark's wholly-owned U.S. dermatology subsidiary; a topical small-molecule treatment being developed for inflammatory skin diseases including psoriasis, planned to enter clinical development.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Soleno Therapeutics: Soleno Therapeutics is developing DCCR (diazoxide choline controlled-release) for hyperphagia in Prader-Willi Syndrome, the same lead indication as Aardvark's ARD-101, making it the most direct head-to-head competitor in PWS.
• Rhythm Pharmaceuticals: Rhythm Pharmaceuticals markets setmelanotide (IMCIVREE) for several rare obesity disorders including BBS and is pursuing PWS; it is the established rare-obesity player that Aardvark would compete with across its lead and follow-on rare metabolic indications.
• Viking Therapeutics: Viking Therapeutics is a clinical-stage biopharma developing oral and injectable obesity therapies (e.g., VK2735), competing with Aardvark in the broader obesity treatment race and sharing the small-cap clinical-stage biotech profile.
• Structure Therapeutics: Structure Therapeutics is developing oral GLP-1 receptor agonists (e.g., GSBR-1290) for obesity and type 2 diabetes, making it a direct competitor to Aardvark's oral, gut-restricted obesity strategy.
• Terns Pharmaceuticals: Terns Pharmaceuticals is a clinical-stage company developing oral obesity therapies including TERN-601, a small-molecule GLP-1 agonist, putting it in direct competition with Aardvark's oral obesity positioning.

Broad incumbents

• Eli Lilly: Eli Lilly markets Mounjaro/Zepbound (tirzepatide) and has a deep oral obesity pipeline, setting the dominant standard of care that Aardvark's oral, hunger-focused approach must differentiate against.
• Novo Nordisk: Novo Nordisk markets Ozempic/Wegovy (semaglutide) and is advancing oral semaglutide, making it the incumbent GLP-1 leader whose scale, manufacturing, and reimbursement reach define the competitive ceiling for Aardvark's obesity ambitions.

Emerging players

• Rivus Pharmaceuticals: Rivus Pharmaceuticals is developing controlled metabolic accelerators (e.g., HU6) for obesity and metabolic disease, representing a parallel small-molecule, mechanism-distinct approach to Aardvark's TAS2R platform.
• Keros Therapeutics: Keros Therapeutics is a clinical-stage biotech developing therapeutics for hematological and musculoskeletal disorders with metabolic components, sharing the small-cap clinical-stage profile and similar investor base as Aardvark.
• Lexicon Pharmaceuticals: Lexicon Pharmaceuticals is developing small-molecule drug candidates in diabetes, metabolism, and pain, overlapping with Aardvark in metabolic disease R&D and representing a comparable small-cap clinical-stage peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/aardvarktherapeutics
• LinkedInlinkedin.com/company/aardvark-therapeutics
• Instagraminstagram.com/aardvarktherapeutics

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aardvark Therapeutics